Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
By Jim Kling. November 7th 2024. Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to target the BCR-ABL fusion in chronic myelogenous leukemia. FDA Grants Orphan …
Potential Synergies With T-Cell Engagers
1 day ago · Joshua K. Sabari, MD, discusses the potential treatment synergies expected from combining MK-6070, a trispecific T-cell engager, with ifinatamab deruxtecan, noting that specific patient and disease factors (eg, tumor expression profiles and previous treatment responses) could influence the decision to pursue dual T-cell engager therapy in early clinical development.
Comparing Dosing Schedules With Standard Therapies
1 day ago · Comparing Dosing Schedules With Standard Therapies. Joshua K. Sabari, MD, discusses how the dosing schedule of ifinatamab deruxtecan offers advantages in terms of simplicity and treatment adherence vs topotecan and lurbinectedin, suggesting that it may enhance the overall quality of life for patients undergoing treatment for SCLC.
Checkpoint Inhibition and Targeted Therapy Move the Needle in ...
4 days ago · Combining the checkpoint inhibitor atezolizumab with targeted therapy led to improvements in overall survival in patients with anaplastic thyroid cancer. Atezolizumab (Tecentriq) plus targeted therapy demonstrated longer median overall survival (OS) compared with historic controls in patients with anaplastic thyroid cancer, according to ...
Luspatercept, Improved Diagnostics Deliver in MDS
4 days ago · The latest development in the treatment landscape for MDS has been the findings from the phase 3 COMMANDS trial (NCT03682536; VISUAL SYNOPSIS). Investigators evaluated luspatercept vs the erythropoiesis-stimulating agent (ESA) epoetin alfa in 350 patients with very low-risk, low-risk, or intermediate-risk MDS.
FDA Clears Phase 2 Trial of Leronlimab for Microsatellite-Stable CRC
6 days ago · The FDA recently approved a phase 2 clinical trial to investigate the efficacy of leronlimab in patients with relapsed or refractory microsatellite-stable metastatic colorectal cancer. CytoDyn, the biotechnology company developing leronlimab, finalized the protocol of a phase 2 study evaluating the agent and gained regulatory clearance.
The Targeted Pulse: Discover the Latest From ODAC and Recent …
Oct 6, 2024 · Olomorasib/Pembrolizumab Shows Promising Response Rates in NSCLC. Olomorasib (LY3537982; 50 mg or 100 mg) plus pembrolizumab (Keytruda) showed favorable overall response rates in the first line setting for patients KRAS G12C–mutated metastatic non–small cell lung cancer, regardless of PD-L1 expression. These data are from the phase 1/2 LOXO-RAS-20001 study (NCT04956640) and presented at ...
Breast Cancer | Oncology News & Insights - Targeted Oncology
Nov 1, 2024 · Participants Consider the Necessity of Chemo in HER2+ Breast Cancer. Targeted Oncology Staff. August 22nd 2024. During a Case-Based Roundtable® event, Ian Krop, MD, PhD, discussed the use of chemotherapy in patients with HER2- and hormone receptor–positive metastatic breast cancer in combination with trastuzumab.
Less Toxic, More Personalized Treatments on the Horizon in …
Sep 12, 2024 · The APT trial was a single-arm, phase 2 trial evaluating patients with node-negative, HER2-positive breast cancer measuring 3 cm or less who received paclitaxel weekly for 12 weeks in combination with trastuzumab for 1 year.1 The final planned analysis of the APT trial showed a 10-year invasive disease-free survival of 91.3% with trastuzumab.
Melanoma - Targeted Oncology
Similar Efficacy in Melanoma Shown in Indirect Comparison of PD-1/LAG3 vs PD-1/CTLA-4. Targeted Oncology Staff. July 16th 2024. During a Case-Based Roundtable® event, Michael A. Postow, MD, discussed an indirect treatment comparison of nivolumab plus relatlimab vs nivolumab plus ipilimumab in patients with advanced melanoma in the second ...